Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

301. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review

The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review Wulffele M G, Kooy A, De Zeeuw D, Stehouwer C D, Gansevoort R T CRD summary This review examined the effects (...) of metformin on blood-pressure and lipid profile in type 2 diabetes. The authors concluded that metformin reduces total and low-density lipoprotein cholesterol slightly more than control treatments but has no effect on other outcomes. The review included a large number of trials and was reasonably well-conducted, and the authors' conclusions are likely to be reliable. Authors' objectives To assess the efficacy of metformin in lowering the blood-pressure (BP) and lipid profile in patients

DARE.2004

302. Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the UK

Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the UK Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the UK Health and economic impact of combining metformin with nateglinide to achieve glycemic control: comparison of the lifetime costs of complications in the UK Ward A J, Salas M, Caro J J (...) , Owens D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology This article assessed the impact of adding nateglinide (360 mg/day) to metformin (1,500 mg/day) in patients with glycaemic problems. Type of intervention Treatment. Economic

NHS Economic Evaluation Database.2004

303. Intensive lifestyle changes of metformin in patients with impaired glucose tolerance: modelling the long-term health economic implications of the Diabetes Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom

Intensive lifestyle changes of metformin in patients with impaired glucose tolerance: modelling the long-term health economic implications of the Diabetes Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom Intensive lifestyle changes of metformin in patients with impaired glucose tolerance: modelling the long-term health economic implications of the Diabetes Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom Intensive (...) lifestyle changes of metformin in patients with impaired glucose tolerance: modelling the long-term health economic implications of the Diabetes Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom Palmer A J, Roze S, Valentine W J, Spinas G A, Shaw J E , Zimmet P Z Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions

NHS Economic Evaluation Database.2004

305. Metformin and thiazolidinedione use in Medicare patients with heart failure.

Metformin and thiazolidinedione use in Medicare patients with heart failure. CONTEXT: According to package inserts, metformin is contraindicated in diabetic patients receiving drug treatment for heart failure therapy, and thiazolidinediones are not recommended in diabetic patients with symptoms of advanced heart failure. Little is known about patterns of use of these antihyperglycemic drugs in diabetic patients with heart failure. OBJECTIVE: To determine the proportions of patients hospitalized (...) with heart failure and concomitant diabetes treated with metformin or thiazolidinediones. DESIGN: Serial cross-sectional measurements using data from retrospective medical record abstraction. SETTING: Nongovernmental acute care hospitals in the United States. PATIENTS: Two nationally representative samples of Medicare beneficiaries hospitalized with the primary diagnosis of heart failure and concomitant diabetes between April 1998 and March 1999 and between July 2000 and June 2001. MAIN OUTCOME MEASURES

JAMA2003

306. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome.

Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Use of metformin in polycystic ovary syndrome (PCOS) is becoming increasingly accepted and widespread, but clinical practice is ahead of the evidence. Although a wide range of benefits in metabolic, reproductive, and clinical measures have been reported from non-randomised trials with metformin, close inspection of results from the adequately controlled studies shows that the benefits are modest. Our aim (...) in this descriptive review is not to define practice guidelines but to improve clinicians' knowledge of the available published clinical evidence, concentrating on the few randomised controlled trials. We also highlight other issues, including hirsutism, acne, pregnancy, and neonatal outcome, that require more attention before clinical recommendations for the use of metformin in PCOS can be formalised. The potentially greater benefits achievable by lifestyle changes alone are also emphasised. We hope

Lancet2003

307. A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome

A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome Costello M F, Eden J A CRD summary This review assessed the effectiveness of metformin in restoring regular menstrual cycles and ovulation, and in achieving pregnancy (...) in women with polycystic ovary syndrome. The authors' concluded that effectiveness was difficult to assess from the available evidence. Although not without some methodological limitations, the authors' conclusions were reasonable and identified where there was insufficient evidence for conclusions to be drawn. Authors' objectives To assess the effectiveness of metformin in restoring regular menstrual cycles and ovulation, and in achieving pregnancy in women with polycystic ovary syndrome (PCOS

DARE.2003

308. Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes

Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes The Diabetes Prevention Program Research Group Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) %. This was reinforced by monthly individual and group sessions. The second intervention was 850 mg of metformin administered orally once per day, increasing to 850mg twice daily after one month. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised patients with impaired glucose tolerance, who were older than 25 years and who had a body mass index of greater than 24 kg/m2. The trial used 3,234 patients (68% women), with an average age

NHS Economic Evaluation Database.2003

309. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. BACKGROUND: Metformin is an oral anti-hyperglycemic agent used in the treatment of type 2 diabetes mellitus. The results of the UK Prospective Diabetes Study indicate that metformin treatment is associated with a reduction in total mortality compared to other anti-hyperglycemic treatments. Metformin, however, is thought to increase the risk of lactic acidosis, and is considered to be contraindicated (...) in many chronic hypoxemic conditions that may be associated with lactic acidosis, such as cardiovascular, renal, hepatic and pulmonary disease, and advancing age. OBJECTIVES: To assess the incidence of fatal and nonfatal lactic acidosis with metformin use compared to placebo and other glucose-lowering treatments in patients with type 2 diabetes mellitus. A secondary objective was to evaluate the blood lactate levels for those on metformin treatment compared to placebo or non-metformin therapies

Cochrane2003

310. Metformin: an update.

Metformin: an update. Metformin is an insulin-sensitizing agent with potent antihyperglycemic properties. Its efficacy in reducing hyperglycemia in type 2 diabetes mellitus is similar to that of sulfonylureas, thiazolidinediones, and insulin. Metformin-based combination therapy is often superior to therapy with a single hypoglycemic agent. The antihyperglycemic properties of metformin are mainly attributed to suppressed hepatic glucose production, especially hepatic gluconeogenesis (...) , and increased peripheral tissue insulin sensitivity. Although the precise mechanism of hypoglycemic action of metformin remains unclear, it probably interrupts mitochondrial oxidative processes in the liver and corrects abnormalities of intracellular calcium metabolism in insulin-sensitive tissues (liver, skeletal muscle, and adipocytes) and cardiovascular tissue.

Annals of Internal Medicine2002

311. Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of Type 2 diabetes mellitus

Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of Type 2 diabetes mellitus Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of Type 2 diabetes mellitus Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin (...) and postprandial glucose levels in a model of Type 2 diabetes mellitus Salas M, Ward A, Caro J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Combination therapy with nateglinide and metformin was compared with metformin monotherapy

NHS Economic Evaluation Database.2002

312. Metformin associated lactic acidosis following administration of intravenous contrast media

Metformin associated lactic acidosis following administration of intravenous contrast media Metformin associated lactic acidosis following administration of intravenous contrast media Metformin associated lactic acidosis following administration of intravenous contrast media Jackson N Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Jackson N. Metformin (...) associated lactic acidosis following administration of intravenous contrast media. Centre for Clinical Effectiveness (CCE). Evidence Centre Evidence Report. 2002 Authors' objectives This aim of this report was to assess the risk associated with contrast agents and patients on Metformin. Authors' conclusions - Findings from a systematic review and a case series have shown that Metformin related lactic acidosis occurs mainly in patients with abnormal renal function. For this reason the authors agree

Health Technology Assessment (HTA) Database.2002

313. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. 11832527 2002 02 08 2002 02 20 2016 10 25 1533-4406 346 6 2002 Feb 07 The New England journal of medicine N. Engl. J. Med. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. 393-403 Type 2 diabetes affects approximately 8 percent of adults in the United States. Some risk factors--elevated plasma glucose concentrations in the fasting state and after an oral glucose load (...) , overweight, and a sedentary lifestyle--are potentially reversible. We hypothesized that modifying these factors with a lifestyle-intervention program or the administration of metformin would prevent or delay the development of diabetes. We randomly assigned 3234 nondiabetic persons with elevated fasting and post-load plasma glucose concentrations to placebo, metformin (850 mg twice daily), or a lifestyle-modification program with the goals of at least a 7 percent weight loss and at least 150 minutes

NEJM2002 Full Text: Link to full Text with Trip Pro

314. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. BACKGROUND: Metformin is an oral anti-hyperglycemic agent used in the treatment of type 2 diabetes mellitus. The results of the UK Prospective Diabetes Study indicate that metformin treatment is associated with a reduction in total mortality compared to other anti-hyperglycemic treatments. Metformin, however, is thought to increase the risk of lactic acidosis, and is considered to be contraindicated (...) in many chronic hypoxemic conditions that may be associated with lactic acidosis, such as cardiovascular, renal, hepatic and pulmonary disease, and advancing age. OBJECTIVES: To assess the incidence of fatal and nonfatal lactic acidosis with metformin use compared to placebo and other glucose-lowering treatments in patients with type 2 diabetes mellitus. A secondary objective was to evaluate the blood lactate levels for those on metformin treatment compared to placebo or non-metformin therapies

Cochrane2002

315. Metformin in non-alcoholic steatohepatitis.

Metformin in non-alcoholic steatohepatitis. There is no established treatment for steatohepatitis in patients who are not alcoholics. This disease is a potentially progressive liver disease associated with hepatic insulin resistance. Only a weight-reducing diet in overweight patients has proved effective. We treated 20 patients who had steatohepatitis but were not alcoholics with metformin (500 mg three times a day for 4 months), an agent that improves hepatic insulin sensitivity. When compared (...) with the six individuals not complying with treatment, long-term metformin significantly reduced mean transaminase concentrations, which returned to normal in 50% of actively-treated patients. Also, insulin sensitivity improved significantly and liver volume decreased by 20%. Similar data have been reported in insulin-resistant ob/ob mice with fatty liver. A randomised-controlled study is needed.

Lancet2001

316. Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis'

Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis' Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis' Lactic acidosis in metformin therapy: searching for a link with metformin in reports of 'metformin-associated lactic acidosis' Lalau J D, Race J M Authors' objectives To review all reports of lactic acidosis in metformin-treated patients (...) published since May 1995, to try to establish the link between metformin and the onset of lactic acidosis. Searching BIOSIS Previews, MEDLINE, EMBASE, Pascal and a Derwent database were searched for literature published in any language from May 1995 to January 2000. The search terms were not reported. Study selection Study designs of evaluations included in the review The authors seem to have searched for single case reports and case series. Specific interventions included in the review Metformin

DARE.2001

317. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No 51)

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No 51) Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No 51) Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS No 51) Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, Stratton I, Holman R Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study investigated the use of metformin (500 to 2,550 mg/day as required) as an agent for intensive blood-glucose control in overweight patients with Type II

NHS Economic Evaluation Database.2001

318. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes

Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes Applying some UK Prospective Diabetes Study results to Switzerland: the cost (...) -effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes Palmer A J, Sendi P P, Spinas G A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of metformin

NHS Economic Evaluation Database.2000

319. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial.

Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. 10904511 2000 08 08 2000 08 08 2016 10 17 0098-7484 284 4 2000 Jul 26 JAMA JAMA Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. 472-7 A syndrome of lipodystrophy, characterized by fat redistribution and insulin resistance, has been estimated to affect the majority of human immunodeficiency virus (HIV)-infected individuals who are treated with combination (...) antiretroviral therapy. There are no proven therapies for the metabolic disturbances associated with HIV lipodystrophy syndrome. To determine the safety and efficacy of metformin therapy in HIV-infected patients with fat redistribution and abnormal glucose homeostasis. Randomized, double-blind, placebo-controlled pilot study conducted in a university hospital between December 1998 and January 2000. Twenty-six HIV-infected, nondiabetic patients with fat redistribution and abnormal oral

JAMA2000

320. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. 10755495 2000 04 13 2000 04 13 2016 10 17 0098-7484 283 13 2000 Apr 05 JAMA JAMA Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. 1695-702 Most antidiabetic agents target only 1 of several underlying causes of diabetes. The complementary actions of the antidiabetic agents metformin (...) hydrochloride and rosiglitazone maleate may maintain optimal glycemic control in patients with type 2 diabetes; therefore, their combined use may be indicated for patients whose diabetes is poorly controlled by metformin alone. To evaluate the efficacy of metformin-rosiglitazone therapy in patients whose type 2 diabetes is inadequately controlled with metformin alone. Randomized, double-blind, placebo-controlled trial from April 1997 and March 1998. Thirty-six outpatient centers in the United States. Three

JAMA2000